| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 29 |
| 1 | NALTREXONE | 28 |
| 2 | RITUXIMAB | 22 |
| 3 | CYCLOPHOSPHAMIDE | 20 |
| 4 | CYCLOPHOSPHAMIDE FOR INJECTION | 20 |
| 5 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 20 |
| 6 | ADALIMUMAB-AATY | 19 |
| 7 | ADALIMUMAB-ADAZ | 19 |
| 8 | ADALIMUMAB-FKJP | 19 |
| 9 | METHOTREXATE SODIUM | 19 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | MALATHION | 1 | 0.0099 |
| 1 | BELINOSTAT | 2 | 0.0056 |
| 2 | CAMPHOR, EUCALYPTUS OIL, MENTHOL | 1 | 0.0043 |
| 3 | AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, OXYBENZONE | 1 | 0.0042 |
| 4 | FEXOFENADINE HYDROCHLORIDE TABLETS | 1 | 0.0039 |
| 5 | SPESOLIMAB | 1 | 0.0025 |
| 6 | AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE | 1 | 0.0022 |
| 7 | TAFASITAMAB-CXIX | 2 | 0.0022 |
| 8 | PLATINUM | 1 | 0.0019 |
| 9 | OXYMETAZOLINE HCL | 1 | 0.0018 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 42 |
| 1 | Tumor Necrosis Factor Blocker [EPC] | 41 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 26 |
| 3 | Alkylating Drug [EPC] | 21 |
| 4 | Kinase Inhibitor [EPC] | 19 |
| 5 | Nonsteroidal Anti-inflammatory Drug [EPC] | 17 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 17 |
| 7 | Proteasome Inhibitor [EPC] | 17 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 15 |
| 9 | Thalidomide Analog [EPC] | 15 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-36 Receptor Antagonist [EPC] | 1 | 0.0025 |
| 1 | Histone Deacetylase Inhibitor [EPC] | 6 | 0.0015 |
| 2 | Antiparasitic [EPC] | 7 | 0.0015 |
| 3 | Pediculicide [EPC] | 7 | 0.0015 |
| 4 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 5 | CD38-directed Cytolytic Antibody [EPC] | 7 | 0.0012 |
| 6 | Pyrethroid [EPC] | 2 | 0.0011 |
| 7 | CD22-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 8 | Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC] | 1 | 0.0003 |
| 9 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |